Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study [Head and Neck Cancer]

Conclusion
Addition of lapatinib to chemoradiotherapy and its use as long-term maintenance therapy does not offer any efficacy benefits and had additional toxicity compared with placebo in patients with surgically treated high-risk SCCHN.

Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Harrington, Temam, Mehanna, D'Cruz, Jain, D'Onofrio, Manikhas, Horvath, Sun, Dietzsch, Dubinsky, Holeckova, El-Hariry, Franklin, Biswas-Baldwin, Legenne, Wissel, Netherway, Farrell, Ellis, Wang-Silvanto, Amonkar, Ahmed, Santillana, Bourhis Tags: Radiation, Chemotherapy, Combined Modality Head and Neck Cancer Source Type: research